

Wednesday, November 7, 2018

10 a.m. – 8 p.m. **Registration**

Location: L St. Bridge

IMMUNE ESCAPE: CURRENT UNDERSTANDING OF MECHANISMS AND ADVANCES IN THERAPEUTICS APPROACHES

Location: East Salon ABC

2 – 2:05 p.m. **Introduction**

Daniel S. Chen, MD, PhD – *IMG Biosciences*

Session I: Therapeutic Strategies to Overcome Immune Resistance

2:05 – 2:25 p.m. **Mechanisms of Immune Escape to Checkpoint Inhibitors**

Priti Hegde, PhD – *Genentech*

2:25 – 2:40 p.m. **A Novel Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy**

Brent A. Hanks, MD, PhD – *Duke University Medical Center*

2:40 – 2:55 p.m. **Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-small Cell Lung Cancer**

Grace Dy, MD – *Roswell Park Comprehensive Cancer Center*

2:55 – 3:10 p.m. **Melanoma Tissue Microarray Characterization with Digital Spatial Profiling Identifies Biomarkers of Clinical Response to Immunotherapy**

David Rimm, MD, PhD – *Yale University*

3:10 – 3:25 p.m. **Primary and Secondary Mechanisms of Resistance to Autologous Anti-CD19 CAR T cell Therapy in Refractory Non-Hodgkin's Lymphoma (rNHL)**

John Rossi, MD – *Kite Pharma*

3:25 – 3:45 p.m. **Group Discussion**

3:45 – 4:00 p.m. **Break**

4:00 – 5:00 p.m. **Panel Discussion: Can CAR T cells Overcome and Influence Resistance to Other Treatment Modalities & New Concepts in Immune Checkpoints Blockade Designed to Overcome Local Immune Resistance**

Co-Moderators: Adrian Bot, PhD – *Kite a Gilead Company*

Eric H. Rubin, MD – *Merck*

Panelists: Daniel S. Chen, MD, PhD – *IMG Biosciences*

Gordon J. Freeman, PhD – *Dana-Farber Cancer Institute*

Carl H. June, MD – *University of Pennsylvania*

Alan Korman, PhD – *Bristol-Myers Squibb*

Marcela Maus, MD, PhD – *Massachusetts General Hospital*

Session II: Underlying Mechanisms of Immune Escape

5:00 – 5:15 p.m. **Analysis of TIL from Human Carcinoma Combined with Tissue Imaging and in vitro Models Uncovers Tumor-inflicted T Cell Deviations Related to Immune Escape and Strategies of Intervention**

Elfriede Noessner, PhD – *Helmholtz Zentrum Munchen*

5:15 – 5:30 p.m. **Impact of Tumor Inherent Interferons on Immune Reactivity and Personalized Therapy in Triple Negative Breast Cancer**

Natasha K. Brockwell, BBiomed (Hons) – *La Trobe Institute for Molecular Science*

5:30 – 5:45 p.m. **Repurposing Anti-Pathogen Vaccines to Overcome Immune Escape within the Tumor Microenvironment**

Andrew Zloza, MD, PhD – *Rutgers Cancer Institute of New Jersey*

5:45 – 6:00 p.m. **First in Human Data in Advanced Solid Tumors of NANT Cancer Vaccine: A Novel Temporospatial Orchestration of the Innate (NK) & Adaptive Immune System to Induce Antigen Cascade & Immunogenic Cell Death**

Patrick Soon-Shiong – *NANT Cancer Immunotherapy, Inc.*

6:00 – 6:20 p.m. **Group Discussion**

6:20 – 6:35 p.m. **Break**

6:35 – 7:35 p.m. **Panel Discussion: Using Oncolytic Immunotherapy to Overcome Immune Resistance in the Tumor Microenvironment & Immune Resistance and the Tumor Microenvironment**

Co-Moderators: Alessandra Cesano, MD, PhD – *NanoString Inc.*

Howard L. Kaufman, MD, FACS – *Replimune Group Inc.*

Panelists: Robert Coffin, PhD – *Replimune Group Inc.*

George Coukos, MD, PhD – *University of Lausanne*

Francesco M. Marincola, MD – *Refuge Biotechnologies*

Ira Mellman, PhD – *Genentech*

Ryan Sullivan, MD – *Massachusetts General Hospital*

Dmitriy Zamarin, MD, PhD – *Memorial Sloan Kettering Cancer Center*

7:35 – 7:55 p.m. **Underlying Mechanisms of Immune Escape**

Thomas F. Gajewski, MD, PhD – *University of Chicago*

7:55 – 8 p.m. **Closing**

Salil Patel, PhD – *Bristol-Myers Squibb*

8 – 9 p.m. **Industry Networking Reception**

Location: East Salon Foyer

Thursday, November 8, 2018

6:30 – 7 p.m. **Registration**
Location: L St. Bridge

6:30 – 8 a.m. **Breakfast**
Location: Hall E Foyer

PRIMER ON TUMOR IMMUNOLOGY AND CANCER IMMUNOTHERAPY™

Location: East Salon ABC

8 – 8:05 a.m. **Introduction**
Timothy NJ Bullock, PhD – *University of Virginia*

Session I: Generating Anti-Tumor Immunity

8:05 – 8:35 a.m. **Adaptive Immunity to Tumors: Laying the Foundation for Immunotherapy**
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

8:35 – 9:05 a.m. **Dendritic Cells**
Tyler Curiel, MD – *UT Health San Antonio*

9:05 – 9:35 a.m. **Harnessing Natural Killer Cells to Potentiate Antitumor Immunity**
Amir Horowitz, PhD – *Icahn School of Medicine at Mount Sinai*

9:35 – 9:55 a.m. **Panel Discussion**

9:55 – 10:10 a.m. **Break**

Session II: Breaking Through the Barriers – Passive Immunotherapy

10:10 – 10:15 a.m. **Introduction**
Timothy NJ Bullock, PhD – *University of Virginia*

10:15 – 10:45 a.m. **Cancer Vaccines : From Ex Vivo Production to In Vivo Vaccination**
Tanja de Gruijl, PhD – *VU University Medical Center*

10:45 – 11:15 a.m. **Monoclonal Antibodies and Their Derivatives**
Charles G. Drake, MD, PhD – *Columbia University Medical Center*

11:15 – 11:45 a.m. **Cytokines**
Kim A. Margolin, MD – *City of Hope*

11:45 – 12:05 p.m. **Panel Discussion**

12:05 – 1:05 p.m. **Lunch**
Location: 101

Session III: Analysis of Resistance and Response

1:05 – 1:10 p.m. **Introduction**
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

1:10 – 1:40 p.m. **Mechanisms of Extrinsic Resistance : A Miserable Microenvironment**
Michael A. Curran, PhD – *University of Texas MD Anderson Cancer Center*

1:40 – 2:10 p.m. **Mechanisms of Resistance: Checkpoint Receptors**
Julie R. Brahmer, MD – *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins*

2:10 – 2:40 p.m. **A High-dimensional Assay and Analysis Platform to Discover Immune Correlates of Cancer Immunotherapy**
Sacha Gnjatic, PhD – *Icahn School of Medicine at Mount Sinai*

2:40 – 3:10 p.m. **Panel Discussion**

3:10 – 3:25 p.m. **Break**

Session IV: Current IO Immunotherapy

3:25 – 3:30 p.m. **Introduction**
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

3:30 – 4 p.m. **Adoptive Cell Therapy**
Patrick Hwu, MD – *University of Texas MD Anderson Cancer Center*

4 – 4:30 p.m. **Combination Therapies**
Leisha A. Emens, MD, PhD – *University of Pittsburgh*

4:30 – 4:50 p.m. **Panel Discussion**

4:50 – 5 p.m. **Closing**
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

Thursday, November 8, 2018

6:30 a.m. – 7 p.m. **Registration**
Location: L St. Bridge

6:30 – 8 a.m. **Breakfast**
Location: Hall E Foyer

WORKSHOP ON NUTRITION, METABOLISM AND THE MICROBIOME IN CANCER THERAPY

Location: 202AB

8 – 8:05 a.m. **Introduction**
Laurence Zitvogel, MD, PhD – *Institute Gustave Roussy*

Session I: The Impact of the Microbiome on Cancer Therapy

8:05 – 8:30 a.m. **The Evolving Role of the Microbiome on Response to Cancer Therapy**
Laurence Zitvogel, MD, PhD – *Institute Gustave Roussy*

8:30 – 9 a.m. **Mechanistic Insights Into the Influence of Gut Microbiota on Anti-Tumor Immunity**
Thomas F. Gajewski, MD, PhD – *University of Chicago*

9 – 9:30 a.m. **The Microbiome as a Biomarker and a Therapeutic Target**
Jennifer Wargo, MD, MMSc - *University of Texas MD Anderson Cancer Center*

9:30 – 9:45 a.m. **Panel Discussion**
Moderator: Laurence Zitvogel, MD, PhD – *Institute Gustave Roussy*
Panelists: Thomas F. Gajewski, MD, PhD – *University of Chicago*
Jennifer Wargo, MD, MMSc - *University of Texas MD Anderson Cancer Center*

9:45 – 10 a.m. **Break**

Session II: Interplay of Nutrition, Metabolism, and the Microbiome

10 – 10:30 a.m. **The Influence of Nutrition on the Microbiome and Immune Function**
Guido Kroemer, MD, PhD – *Institute Gustave Roussy*

10:30 – 11 a.m. **Harnessing Diet and the Microbiome for Cancer Patients and Survivors**
Carrie Daniel-MacDougall, MPH, PhD – *University of Texas MD Anderson Cancer Center*

- 11 – 11:30 a.m. **Homeostatic and Inflammatory Immune Responses to Human Microbiotas in Gnotobiotic Mice**
Graham Britton, PhD – *Icahn School of Medicine at Mount Sinai*
- 11:30 a.m. – 12 p.m. **The Interplay Between Diet, Intestinal Microbiota and Colorectal Cancer**
Christian Jobin, PhD – *University of Florida*
- 12 – 1 p.m. **Panel Discussion**
Graham Britton, PhD – *Icahn School of Medicine at Mount Sinai*
Carrie Daniel-MacDougall, MPH, PhD – *University of Texas MD Anderson Cancer Center*
Thomas F. Gajewski, MD, PhD – *University of Chicago*
Christian Jobin, PhD – *University of Florida*
Guido Kroemer, MD, PhD – *Institute Gustave Roussy*
Jennifer Wargo, MD, MMSc - *University of Texas MD Anderson Cancer Center*
Laurence Zitvogel, MD, PhD – *Institute Gustave Roussy*

Thursday, November 8, 2018

6:30 a.m. – 7 p.m. **Registration**
Location: L St. Bridge

6:30 – 8 a.m. **Breakfast**
Location: Hall E Foyer

FDA/SITC Co-Sponsored Workshop

Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials

Location: 202AB

2 – 2:10 p.m. **Introduction**
Marc Theoret, MD – *U.S. Food & Drug Administration, OHOP*
Howard Kaufman, MD, FACS – *Replimune Group Inc.*

Session I: Pseudoprogession with Immuno-oncology Therapeutics - Current Challenges with Evaluation of Surrogate Endpoints with Immuno-oncology Drug Products

2:10 – 2:30 p.m. **Pseudoprogession and Current Clinical Challenges in the Management of Patients on Immuno-oncology Therapy**
Kim A. Margolin, MD – *City of Hope*

2:30 – 2:50 p.m. **Immune-Modified Response Criteria in Clinical Development Programs of Immuno-oncology Therapeutics**
Sanjay Goel, MD – *Montefiore Medical Center*

2:50 – 3:10 p.m. **Regulatory Perspectives with Use of Immune-Modified Response Criteria for Assessment of Surrogate Clinical Efficacy Endpoints for Registration Trials**
Patricia Keegan, MD – *U.S. Food & Drug Administration*

3:10 – 3:55 p.m. **Panel Discussion**
Moderator: Marc Theoret, MD – *U.S. Food & Drug Administration, OHOP*
Panelists: Peter F. Bross, MD – *U.S. Food and Drug Administration, CBER*
David Feltquate, MD, PhD – *Bristol-Myers Squibb*
Sanjay Goel, MD – *Montefiore Medical Center*
Patricia Keegan, MD – *U.S. Food & Drug Administration*
Kim A. Margolin, MD – *City of Hope*
Lawrence H. Schwartz, MD – *Columbia University College of Physicians and Surgeons*
Steven Silverstein, MBA – *Melanoma Research Foundation*
Jon Wigginton, MD – *MacroGenics, Inc.*

3:55 – 4:10 p.m. **Break**

Session II: Evaluating Surrogate Endpoints for Immuno-Oncology Drug Development: “New and Renewed” Concepts and Perspectives

4:10 – 4:30 p.m. **Clinical Trial Endpoints Considerations for Evaluating Efficacy in Immuno-Oncology Clinical Trials**
David McDermott, MD – *Beth Israel Deaconess Medical Center*

4:30 – 4:50 p.m. **Beyond Conventional Tumor-Based Measurements: Analysis Considerations for Clinical Efficacy Endpoints to More Fully Capture the Benefit of Immuno-Oncology Therapeutics**
Rajeshwari Sridhara, PhD – *U.S. Food & Drug Administration*

4:50 – 5:10 p.m. **How to Integrate Biomarkers and Other Correlates of Response into the Regulatory Landscape**
Genevieve Boland, MD, PhD – *Massachusetts General Hospital*

5:10 – 5:55 p.m. **Panel Discussion**

Moderator: Howard Kaufman, MD, FACS – *Replimune Group Inc.*

Panelists: Genevieve Boland, MD, PhD – *Massachusetts General Hospital*

Samir Khleif, MD – *Georgetown University*

Ke Liu, MD, PhD – *U.S. Food and Drug Administration, CBER*

David McDermott, MD – *Beth Israel Deaconess Medical Center*

Reena Philip, PhD – *U.S. Food & Drug Administration*

Meredith Regan, ScD – *Dana-Farber Cancer Institute*

Lawrence H. Schwartz, MD – *Columbia University College of Physicians and Surgeons*

Rajeshwari Sridhara, PhD – *U.S. Food & Drug Administration*

5:55 – 6 p.m.

Closing

Michael B. Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

Ke Liu, MD, PhD – *U.S. Food and Drug Administration, CBER*

Thursday, November 8, 2018

6:30 a.m. – 7 p.m. **Registration**
Location: L St. Bridge

6:30 – 8 a.m. **Breakfast**
Location: Hall E Foyer

GRANT WRITING: FROM START TO FINISH, AND THEN STARTING AGAIN

Location: 204BC

6:30 – 6:35 p.m. **Introduction**
Jennifer L. Guerriero, PhD – *Dana-Farber Cancer Institute*

6:35 – 6:55 p.m. **Obtaining Funding in Academia - Identifying and Selecting the Appropriate Grant**
Pawel Kalinski, MD, PhD – *Roswell Park Comprehensive Cancer Institute*

6:55 – 7:15 p.m. **Obtaining Funding in Academia - Mechanics of Grant Writing**
Thomas F. Gajewski, MD, PhD – *University of Chicago*

7:15 – 7:35 p.m. **NIH/NCI Grants: The NIH Grant Review Process**
Denise Shaw, PhD – *National Institutes of Health*

7:35 – 7:55 p.m. **Melanoma Research Alliance (MRA)/Foundation Funding**
Kristen Mueller, PhD – *Melanoma Research Alliance*

7:55 – 8:25 p.m. **Panel Discussion**

8:25 – 8:30 p.m. **Closing**
Ana Carrizosa Anderson, PhD – *Harvard Medical School*

8:30 – 9:30 p.m. **Grant Writing Workshop Reception**
Location: 204A

Thursday, November 8 – Sunday, November 11, 2018

33rd ANNUAL MEETING

Thursday, November 8, 2018

6:30 a.m. – 7 p.m. <i>Location:</i>	Registration L St. Bridge
5 – 6:30 p.m. <i>Location:</i>	33rd Annual Meeting Opening Reception Hall E
8:30 – 9:30 p.m. <i>Location:</i>	SITC Sparkathon Alumni Reception Marriott Marquis, Cherry Blossom
9 – 11 p.m. <i>Location:</i>	Early Career Scientist Networking Reception The Dignitary at Marriott Marquis

Friday, November 9, 2018

6:30 a.m. – 7 p.m. <i>Location:</i>	Registration L St. Bridge
7:15 – 8 a.m. <i>Location:</i>	Presidential Champagne Breakfast & Membership Business Meeting Hall D
7:30 – 8:30 a.m. <i>Location:</i>	Breakfast Hall E Foyer
8 – 8:05 a.m. <i>Location:</i>	Presidential Welcome Lisa H. Butterfield, PhD – <i>University of Pittsburgh</i> Hall D
Session 100: Update Session <i>Location:</i>	Hall D
8:05 – 8:20 a.m.	Food & Drug Administration Update: Cell and Gene Therapy Raj Puri, MD, PhD – <i>Food & Drug Administration</i>

8:20 – 8:35 a.m.

Stand Up To Cancer Update

Carl H. June – *University of Pennsylvania*

Session 101: Keynote Address

Location: Hall D

8:35 – 8:40 a.m.

Introduction

Lisa H. Butterfield, PhD – *University of Pittsburgh*

8:40 – 9:20 a.m.

Next Gen T Cell-based Immunotherapy

Nicholas P. Restifo, MD – *National Cancer Institute*

9:20 – 9:25 a.m.

Q&A

Nicholas P. Restifo, MD – *National Cancer Institute*

Session 102: Understanding the Tumor Microenvironment

Co-Chairs:

Bernard A. Fox, PhD – *Earle A. Chiles Research Institute, Robert W. Franz Cancer Center*

Stefani Spranger, PhD – *Koch Institute for Integrative Cancer Research at MIT*

Location: Hall D

9:25 – 9:30 a.m.

Introduction

Bernard A. Fox, PhD – *Earle A. Chiles Research Institute, Robert W. Franz Cancer Center*

9:30 – 9:50 a.m.

Genomic Approaches to the Tumor Microenvironment

Alexandra Snyder Charen, MD – *Merck*

9:50 – 10:10 a.m.

Understanding the Tumor Immune Composition Using Quantitative and Spatially Resolved Imaging Mass Cytometry

Kurt A. Schalper, MD, PhD – *Yale School of Medicine*

10:10 – 10:25 a.m.

Break

10:25 – 10:45 p.m.

Single Cell Genomics – Using a Finer Lens to Unravel Features of Human Immunity

Alexandra-Chloe Villani, PhD – *Harvard Medical School*

10:45 – 11:05 a.m.

Mouse Models of the TME

Tyler Jacks, PhD – *Koch Institute for Integrative Cancer Research at MIT*

11:05 – 11:20 a.m.

Reinvigorating TILs by hyper-oxygenation

Tomasz Zal, PhD – *MD Anderson Cancer Center*

11:20 – 11:35 a.m.

Comparison of biomarker assay modalities in anti-PD-(L)1 monotherapy: a meta-analysis

Steve Lu, BS – *John Hopkins University School of Medicine*

11:35 – 11:55 a.m. **Panel Discussion**

11:55 a.m. – 12 p.m. **Closing**

Stefani Spranger, PhD – *Koch Institute for Integrative Cancer Research at MIT*

Session 103: Late-Breaking Abstract Session

Chair: Crystal Mackall, MD – *Stanford University*

Location: Hall D

12 – 12:15 p.m. **Imaging of tumor infiltrating T cells with an anti-CD8 minibody 89Zr-IAB22M2C in advanced solid tumors: a phase I first-in-human study**

Michael Gordon, MD – *HonorHealth Research Institute*

12:15 – 12:30 p.m. **In silico assessment of variation in TMB quantification across diagnostic platforms: Phase 1 of the Friends of Cancer Research Harmonization Project**

David Fabrizio, PhD – *Foundation Medicine*

12:30 – 12:45 p.m. **Sparkathon Update: Team TimIOs – A Pooled Analysis of Durable versus Transient Responders on Immunotherapy Trials**

Yana Najjar, MD – *University of Pittsburgh*

Randy Sweiss, MD – *University of Chicago*

12:45 – 2:15 p.m. **Lunch; Poster Viewing & Exhibits**

Location: Hall E

Rapid Oral Abstract Presentation Session

Co-Chairs:

Sebastiano Battaglia, PhD – *Roswell Park Comprehensive Cancer Institute*

Claire Vanpouille-Box, PhD – *Weill Cornell Medical College*

Location: 204ABC

1 – 1:05 p.m. **High-dimensional flow cytometry of circulating immune cells predicts clinical responses to combination Immune Checkpoint Blockade (ICB) and Radiotherapy (RT) in Gastroesophageal Cancer (GEC)**

Joseph Chao, MD – *City of Hope Comprehensive Cancer Center*

1:05 – 1:10 p.m. **Fast quality gauging of tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer**

Georgia Paraschoudi, M.Sc. – *Champalimaud Foundation*

1:10 – 1:15 p.m. **Immunologic biomarkers in a multi-center, single arm, open label Phase II clinical trial of mFOLFOX6 and pembrolizumab in patients with advanced colorectal cancer**

Matthew Farren, PhD – *Emory University*

- 1:15 – 1:20 p.m. **Deep learning of the immune synapse**
John- William Sidhom, MSE – *John Hopkins University*
- 1:20 – 1:25 p.m. **Overcoming genetically-based resistance mechanisms to PD-1 blockade**
Davis Torrejon, MD – *UCLA Hematology-Oncology*
- 1:25 – 1:30 p.m. **Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis**
Yinghong Wang, MD, PhD – *University of Texas MD Anderson Cancer Center*
- 1:30 – 1:35 p.m. **Abstract Presentation**
- 1:35 – 1:40 p.m. **Development of a next-generation sequencing-based microsatellite instability assay (MSI-NGS) for solid tumor testing**
Sean Glenn, PhD – *Omniseq, Inc.*
- 1:40 – 1:45 p.m. **Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment**
Sekwon Jang, MD – *iNova/Personalis*
- 1:45 – 1:50 p.m. **Preinfusion product doubling time is associated with CAR T cell expansion and outcomes in ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma**
Frederick L. Locke, MD – *Moffitt Cancer Center*
- 1:50 – 1:55 p.m. **DuoBody-PD-L1x4-1BB combines checkpoint blockade and 4-1BB co-stimulation to promote antigen-specific T-cell stimulation and proliferation**
Isil Altintas, PhD – *Genmab*
- 1:55 – 2 p.m. **Molecular determinants of response to PD-L1 blockade across tumor types**
Romain Banchereau – *Genentech*
- 2 – 2:05 p.m. **CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule**
Alexandre E. Michaux, PhD – *Celyad SA*

Concurrent Session 104: Immune Checkpoints – Beyond PD-1

Co-Chairs:

Ana Carrizosa Anderson, PhD – *Harvard Medical School*

Charles G. Drake, MD, PhD – *Columbia University Medical Center*

Location: Hall D

- 2:15 – 2:20 p.m. **Introduction**
Ana Carrizosa Anderson, PhD – *Harvard Medical School*

- 2:20 – 2:45 p.m. **LAG-3: Signaling, Function and Potential Impact on Cancer Immunotherapy**
Dario A.A. Vignali, PhD – *University of Pittsburgh*
- 2:45 – 3:10 p.m. **The Influence of the Cancer Genome on Efficacy of Immunotherapy in Lung Cancer**
Brian Ruffell, PhD – *Moffitt Cancer Center*
- 3:10 – 3:25 p.m. **Break**
- 3:25 – 3:50 p.m. **Targeting the TIGIT/CD226 Axis in Cancer Immunotherapy**
Hassane M. Zarour, MD – *UPMC Hillman Cancer Center*
- 3:50 – 4:15 p.m. **4-1BB and Metabolism**
Ignacio Melero, MD, PhD – *Clinica Universidad de Navarra-FIMA*
- 4:15 – 4:30 p.m. **Remodeling the tumor microenvironment – Targeting Scavenger receptors**
Dhifaf Sarhan, PhD – *Karolinska Institutet*
- 4:30 – 4:45 p.m. **Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding**
Lawrence P. Andrews, PhD – *University of Pittsburgh*
- 4:45 – 4:50 p.m. **Closing**
Charles G. Drake, MD, PhD – *Columbia University Medical Center*

Concurrent Session 105: Early Phase 1 Clinical Trials

Co-Chairs:

David S. Hong, MD – *University of Texas MD Anderson Cancer Center*

Patricia LoRusso, DO – *Yale University*

Location: East Salon ABC

- 2:15 – 2:20 p.m. **Introduction**
David S. Hong, MD – *University of Texas MD Anderson Cancer Center*
- 2:20 – 2:35 p.m. **Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors**
Dmitriy Zamarin, MD, PhD – *Memorial Sloan Kettering Cancer Center*
- 2:35 – 2:50 p.m. **First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor- β receptor type 1 (TGF- β R1) inhibitor LY3200882 in patients with advanced cancers**
Timothy Yap, MD – *University of Texas MD Anderson Cancer Center*

- 2:50 – 3 p.m. **Expert Discussant**
Zihai Li, MD, PhD – *MUSC Hollings Cancer Center*
- 3 – 3:15 p.m. **The GAPVAC approach of actively personalized peptide vaccination for patients with newly diagnosed glioblastoma**
Hideho Okada, MD, PhD – *University of California, San Francisco, USA and Parker Institute for Cancer Immunotherapy*
- 3:15 – 3:30 p.m. **The Personal Vaccine, NEO-PV-01 with anti-PD1, Induces Neoantigen-Specific De Novo Tumor-Related Immunity in Patients with Advanced Cancer**
Siwen Hu-Lieskovan, MD, PhD – *Ronald Reagan UCLA Medical Center*
- 3:30 – 3:40 p.m. **Expert Discussant**
Drew Pardoll, MD, PhD – *Johns Hopkins University*
- 3:40 – 3:55 p.m. **A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma**
Diwakar Davar, MD – *University of Pittsburgh Department of Medicine*
- 3:55 – 4:10 p.m. **Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, efitlagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma**
Adnam Khattak, MD – *Perth University*
- 4:10 – 4:25 p.m. **The anti-LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study**
Nehal Lakhani, MD, PhD – *START-Midwest*
- 4:25 – 4:40 p.m. **Phase 1 dose-finding study of the anti-TIGIT antibody MK-7684 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors**
Talia Golan – *Sheba Medical Center*
- 4:40 – 4:50 p.m. **Expert Discussant**
Aung Naing, MD, FACP – *University of Texas MD Anderson Cancer Center*
- 4:50 – 5:05 p.m. **Break**

Concurrent Session 106: Cytokines Reinvented

Co-Chairs:

James L. Gulley, MD, PhD, FACP – *National Cancer Institute*

Darrell J. Irvine, PhD – *Massachusetts Institute of Technology*

Location: Hall D

5:05 – 5:07 p.m.

Introduction

James Gulley, MD, PhD, FACP – *National Cancer Institute*

5:07 – 5:27 p.m.

NHS/IL15

Marijo Bilusic, MD, PhD – *National Cancer Institute, National Institutes of Health*

5:27 – 5:47 p.m.

Harnessing Potent Immune Agonist Pathways through Kinetic Engineering

Deborah Charych, PhD

5:47 – 6:07 p.m.

Locoregional Cytokine Immunotherapy

K. Dane Wittrup, PhD – *Massachusetts Institute of Technology*

6:07 – 6:17 p.m.

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma

Adi Diab, MD – *The University of Texas MD Anderson Cancer Center*

6:17 – 6:27 p.m.

Decoy-resistant Interleukin-18 overcomes the soluble immune checkpoint IL-18BP to unlock a potent immunotherapeutic cytokine pathway

Aaron Ring – *Yale School of Medicine*

6:27 – 6:30 p.m.

Closing

Darrell J. Irvine, PhD – *Massachusetts Institute of Technology*

Concurrent Session 107: Metabolic Manipulation of the TME

Co-Chairs:

Greg M. Delgoffe, PhD – *University of Pittsburgh*

Michele W. Teng, PhD – *QIMR Berghofer Medical Research Institute*

Location: East Salon ABC

5:05 – 5:25 p.m.

Targeting the Adenosinerigic Pathway to Improve Combination Immunotherapy

Michele W. Teng, PhD – *QIMR Berghofer Medical Research Institute*

5:25 – 5:45 p.m.

Enhancement of Oncolytic Virus Immunotherapy Through Vector-Encoded Metabolic Modulation of the Tumor Microenvironment

Greg M. Delgoffe, PhD – *University of Pittsburgh*

- 5:45 – 6 p.m. **Chronic endoplasmic reticulum stress drives mitochondrial exhaustion of CD8 TILs**
Jessica Thaxton, PhD MSCR – *Medical University of South Carolina*
- 6 – 6:15 p.m. **Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity**
Esra Akbay, PhD – *University of Texas Southwestern Medical*
- 6:15 – 6:30 p.m. **Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma**
Ashley Menk, BS – *University of Pittsburgh*
- 6:30 – 8 p.m.
Location: **Poster Reception**
Hall E

Saturday, November 10, 2018

7 a.m. – 7 p.m.

Location:

Registration

L St. Bridge

7 – 8 a.m.

Location:

Breakfast

Hall E Foyer

7:20 – 7:25 a.m.

Location:

Annual Meeting Organizer Welcome

Krista M. Rubin, MS, FNP-BC – *Massachusetts General Hospital*

Hall D

Session 200: Update Session

Location:

Hall D

7:25 – 7:40 a.m.

Policy Committee Update

Samir N. Khleif, MD – *Georgetown University*

Session 201: Smalley Keynote

Location:

Hall D

7:40 – 7:45 a.m.

Introduction

Lisa H. Butterfield, PhD – *University of Pittsburgh*

7:45 – 8:25 a.m.

Engineering T cells to Effectively Target Tumors and Overcome Obstacles To Achieving Tumor Eradication

Philip D. Greenberg, MD – *Fred Hutchinson Cancer Research Center*

8:25 – 8:30 a.m.

Q&A

Philip D. Greenberg, MD – *Fred Hutchinson Cancer Research Center*

Session 202: Cell-Based Therapies for Solid Tumors

Co-Chairs:

Chantale Bernatchez, PhD – *University of Texas MD Anderson Cancer Center*

Mitchell Cairo, MD – *New York Medical College At Maria Fareri Children's Hospital*

Crystal Mackall, MD – *Stanford University*

Location:

Hall D

8:30 – 8:35 a.m.

Introduction

Crystal Mackall, MD – *Stanford University*

- 8:35 – 8:55 a.m. **Pre-Clinical Approaches to CAR NK cell Therapy in Neuroblastoma and Sarcomas**
Mitchell S. Cairo, MD – *New York Medical College at Maria Fareri Children's Hospital*
- 8:55 – 9:15 a.m. **CAR T cell Therapies in Glioblastoma**
Christine Brown, PhD – *City of Hope National Medical Center*
- 9:15 – 9:30 a.m. **Break**
- 9:30 – 9:50 a.m. **CAR T cell Therapies in Solid Tumors**
Gianpietro Dotti, MD – *University of North Carolina, Chapel Hill*
- 9:50 – 10:10 a.m. **TIL Therapy for Melanoma and Beyond – Lessons Learned on Optimal Tumor Rejection Antigen for Solid Tumors**
Steven A. Rosenberg, MD, PhD – *National Cancer Institute, National Institutes of Health*
- 10:10 – 10:25 a.m. **Tscm-like CD8+ T-cells are Associated with Adoptive TIL Therapy Response and Survival**
Matthew Beatty, PhD – *Moffitt Cancer Center*
- 10:25 – 10:40 a.m. **Next-generation retroviral vector with membrane-anchored IL-12 to improve adoptive T cell immunotherapy and enhance its safety**
Ling Zhang, PhD – *National Institutes of Health*
- 10:40 – 11 a.m. **Panel Discussion**
- 11 – 11:05 a.m. **Closing**
Chantale Bernatchez, PhD – *University of Texas MD Anderson Cancer Center*

Concurrent Session 203: Update Session

Location: Hall D

- 11:05 – 11:35 a.m. **National Cancer Institute Update: Immuno-oncology Research at the National Cancer Institute**
Norman E. Sharpless, MD – *National Cancer Institute*

Concurrent Session 204: Clinical Management of Cell Therapy Administration

Co-Chairs:

Harriet Kluger, MD – *Yale University*

Krista Rubin, MS, FNP-BC – *Massachusetts General Hospital*

Location: East Salon ABC

- 11:05 – 11:10 a.m. **Introduction**
Harriet Kluger, MD – *Yale University*

- 11:10 – 11:30 a.m. **Tumor Infiltrating Lymphocytes**
Ronnie Shapira-Frommer, MD – *Ella Institute for Immuno-Oncology*
- 11:30 – 11:50 a.m. **Clinical and Biomarker Correlates and Management of Common Cellular Therapy Toxicities Including Cytokine Release Syndrome and Neurotoxicity**
Eric L. Smith, MD, PhD – *Memorial Sloan Kettering Cancer Center*
- 11:50 a.m. – 12:10 p.m. **CAR T Cell Therapy in Pediatric Cancer Treatment**
Shannon L. Maude, MD, PhD – *Children's Hospital of Philadelphia Center for Childhood Cancer Research*
- 12:10 – 12:25 p.m. **Q&A**
- 12:25 – 12:30 p.m. **Closing**
Krista Rubin, MS, FNP-BC – *Massachusetts General Hospital*

Concurrent Session 205: Late-Breaking Abstract Session

Chair: Naiyer A. Rizvi, MD – *Columbia University Medical Center*

Location: Hall D

- 11:35 – 11:50 a.m. **Pembrolizumab in combination with chemoradiotherapy (CRT) in human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)**
Steven F. Powell, MD – *Sanford Cancer Center*
- 11:50 a.m. – 12:05 p.m. **Expert Discussant**
Charles Drake, MD, PhD – *Columbia University Medical Center*

Concurrent Session 206: SITC Sparkathon Update

Location: Hall D

- 12:05 – 12:20 p.m. **Team METIOR Incubator: Strengthening Communication Across Scientific Disciplines**
Alexandra Cadena, BS/BA – *MD Anderson Cancer Center*
Sebastiano Battaglia, PhD – *Roswell Park Cancer Institute*
- 12:20 – 1:50 p.m. **Lunch; Poster Viewing & Exhibits**
Location: Hall E

Rapid Oral Abstract Presentation Session

Chair:

Julie Decock, PhD – *Qatar Biomedical Research Institute*

Location: 204ABC

- 12:35 – 12:40 p.m. **Pharmacodynamic Activity of MEDI1873, a Glucocorticoid-Induced Tumor Necrosis Factor Family-Related protein (GITR) Agonist Molecule, Administered Intravenously to Patients with Advanced Solid Tumors**
Nicholas Durham, PhD – *MedImmune*
- 12:40 – 12:45 p.m. **Intratumoral injection of a novel oncolytic virus, Voyager V1 (VV1): completed phase 1 monotherapy in patients with refractory solid tumors**
Steven Powell, MD – *Sanford Cancer Center*
- 12:45 – 12:50 p.m. **First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors**
Kohei Shitara, MD – *National Cancer Hospital East*
- 12:50 – 12:55 p.m. **Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors**
Sunil Sharma, MD – *Honor Health Research Institute*
- 12:55 – 1 p.m. **A phase 1 study of ALX148: CD47 blockade in combination with anticancer antibodies to bridge innate and adaptive immune responses for advanced malignancy**
Nehal Lakhani, MD, PhD – *START Midwest*
- 1 – 1:05 p.m. **Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced solid tumors or lymphomas**
Funda Meric-Bernstam, MD – *MD Anderson Cancer Center*
- 1:05 – 1:10 p.m. **Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial**
Luc R. Desnoyers, PhD – *CytomX Therapeutics, Inc.*
- 1:10 – 1:15 p.m. **Preliminary Biomarker Analysis of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor**
Kai He, MD, PhD
- 1:15 – 1:20 p.m. **A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with non-small cell lung cancer**
Marcia Brose – *Abramson Cancer Center of the University*

- 1:20 – 1:25 p.m. **HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation HypoMethylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours**
Malaka Ameratunga, MBBS – *Royal Marsden Hospital*
- 1:25 – 1:30 p.m. **Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis**
Daniel Johnson, MD – *MD Anderson Cancer Center*
- 1:30 – 1:35 p.m. **Clinical efficacy of immune checkpoint inhibitors in patients with small cell lung cancer is associated with high tumor mutational burden and development of immune-related adverse events**
Biagio Ricciuti, MD – *Dana-Farber Cancer Institute*
- Session 207: Presidential Session**
Location: Hall D
- 1:55 – 2 p.m. **Introduction**
Lisa H. Butterfield – *University of Pittsburgh*
- 2 – 2:15 p.m. **PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy**
Gabriel Abril-Rodriguez, MS – *University of California, Los Angeles*
- 2:15 – 2:30 p.m. **Adaptive plasticity of IL10+ and IL35+ regulatory T cells and their cooperative regulation of anti-tumor immunity**
Hiroshi Yano, BS – *University of Pittsburgh*
- 2:30 – 2:40 p.m. **Expert Discussant**
Nicholas P. Restifo, MD – *National Cancer Institute*
- 2:40 – 2:55 p.m. **Endoplasmic reticulum stress-induced transcription factor C/EBP homologous protein (Chop) thwarts effector T cell activity in tumors through repression of T-bet**
Yu Cao, PhD – *H. Lee Moffitt Cancer Center & Research Institute*
- 2:55 – 3:10 p.m. **Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors**
Kristin Anderson, PhD – *Fred Hutchinson Cancer Research Center*
- 3:10 – 3:20 p.m. **Expert Discussant**
Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*
- 3:20 – 3:35 p.m. **Break**

Concurrent Session 208: Advances in Immunotherapy of Breast and Gynecologic Cancers

Co-Chairs:

George Plitas, MD – *Memorial Sloan Kettering Cancer Center*

Alessandro Santin, MD – *Yale School of Medicine*

Location: Hall D

3:35 – 3:40 p.m.

Introduction

George Plitas, MD – *Memorial Sloan Kettering Cancer Center*

3:40 – 4:05 p.m.

Advances in Immunotherapy of Gynecologic Malignancies

Dmitriy Zamarin, MD, PhD – *Memorial Sloan Kettering Cancer Center*

4:05 – 4:30 p.m.

Breast Cancer

Sylvia Adams, MD – *New York University Cancer Institute*

4:30 – 4:45 p.m.

Increased tumor-resident memory T cells in breast cancer is associated with improved prognosis

Paul Neeson, PhD – *Peter MacCallum Cancer Centre*

4:45 – 5 p.m.

Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma

David Page, MD – *Providence Portland Medical Center*

Concurrent Session 209: Advances in Immunotherapy of GI and Pancreatic Cancer

Co-Chairs:

Dung T. Le, MD – *The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University*

Herbert J. Zeh, MD – *UT Southwestern Medical Center*

Location: 206

3:35 – 3:40 p.m.

Introduction

Dung T. Le, MD – *The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University*

3:40 – 3:55 p.m.

Augmenting T cell Immunity in Pancreatic Cancer

Stephanie K. Dougan, PhD – *Dana-Farber Cancer Institute*

3:55 – 4:10 p.m.

Reprogramming the Pancreatic Tumor Microenvironment to Improve Responses to Therapy

David G. DeNardo, PhD – *Washington University School of Medicine, St. Louis*

4:10 – 4:25 p.m.

Exploiting the Complex Stromal Biology of Pancreas Cancer

Sunil R. Hingorani, MD, PhD – *Fred Hutchinson Cancer Research Center*

Concurrent Session 211: Advances in Immunotherapy of Hematologic Malignancies

Co-Chairs:

Joshua Brody, MD – *Mount Sinai School of Medicine*

Elizabeth Shpall, MD – *University of Texas MD Anderson Cancer Center*

Location: 201

3:35 – 4 p.m. **Off-The-Shelf Engineered NK Cells for The Treatment of Cancer**
Katayoun Rezvani, MD, PhD – *University of Texas MD Anderson Cancer Center*

4 – 4:25 p.m. **CAR T cells**
Stanley R. Riddell, MD – *Fred Hutchinson Cancer Research Center*

4:25 – 4:45 p.m. **Checkpoint Blockade**
Thomas Marron, PhD – *Mount Sinai Hospital*

4:45 – 5 p.m. **LSD1 Inhibition Promotes CD141Hi Dendritic Cell Differentiation in Myelodysplastic Syndromes**
Pragya Srivastava, PhD – *Roswell Park Comprehensive Cancer Center*

5 – 5:10 p.m. **Break**

Concurrent Session 212: Advances in Immunotherapy of Lung, Head and Neck Cancer

Co-Chairs:

Naiyer A. Rizvi, MD – *Columbia University Medical Center*

Tanguy Seiwert, MD – *University of Chicago*

Location: East Salon ABC

3:35 – 3:40 p.m. **Introduction**
Naiyer A. Rizvi, MD – *Columbia University Medical Center*

3:40 – 4:05 p.m. **The Influence of the Cancer Genome on Efficacy of Immunotherapy in Lung Cancer**
Nadeem Riaz, MD, MSc – *Memorial Sloan Kettering Cancer Center*

4:05 – 4:30 p.m. **Head and Neck Cancer**
Tanguy Seiwert, MD – *University of Chicago*

4:30 – 4:45 p.m. **Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab**
Alessandra Nardin, DVM – *immunoSCAPE*

4:45 – 5 p.m. **Peripheral T cell dynamics in resectable NSCLC patients treated with neoadjuvant PD-1**

blockade

Jiajia Zhang, MD – MPH – *Johns Hopkins University*

Concurrent Session 213: Advances in Immunotherapy of Pediatric Malignancies

Co-Chairs:

Kavita Dhodapkar, MD – *Emory University*

Crystal Mackall, MD – *Stanford University*

Location: 204ABC

3:35 – 3:40 p.m.

Introduction

Kavita Dhodapkar, MD – *Emory University*

3:40 – 4 p.m.

Preventing Relapse After CAR T cell Immunotherapy for B cell Malignancies

Terry J. Fry, MD – *Children's Hospital of Colorado*

4 – 4:20 p.m.

Vaccines Targeting Malignant Brain Tumors

Duane A. Mitchell, MD, PhD – *University of Florida*

4:20 – 4:40 p.m.

Tumor Microenvironment

Kavita M. Dhodapkar, MD – *Emory University*

4:40 – 4:55 p.m.

Characterization of anti-tumor immune responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in spontaneous Osteosarcoma

Kelly Makielski, DVM, MS – *University of Minnesota*

4:55 – 5 p.m.

Closing

Crystal Mackall, MD – *Stanford University*

Concurrent Session 214: Basic Biology of Tregs

Co-Chairs:

Sergio A. Quezada, PhD – *University College London*

Dario A.A. Vignali, PhD – *University of Pittsburgh*

Location: Hall D

5:10 – 5:31 p.m.

Targeting Regulatory T Cells for Therapeutic Gain: Means and Mechanisms

Sergio A. Quezada, PhD – *University College London*

5:31 – 5:51 p.m.

The TNFR2 Treg Receptor and Oncogene: Dominant Antagonistic Antibody Targeting for Cancer

Denise L. Faustman, MD, PhD – *Harvard Medical School*

5:51 – 6:01 p.m.

Lactic acid metabolically supports the high suppressive function of tumor infiltrating regulatory T cells

McLane Watson, BS – *University of Pittsburgh*

6:01 – 6:11 p.m. **Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion**
Erica Stone, PhD – *Wistar Institute*

6:11 – 6:21 p.m. **Neuropilin-1 Stabilizes Human Tregs in Cancer Patients Leading to More Potent Suppressive Function**
Christopher A. Chuckran, BS – *University of Pittsburgh School of Medicine*

6:21 – 6:30 p.m. **Q&A**

Concurrent Session 215: Myeloid Derived Suppressive Populations

Co-Chairs:

Dmitry I. Gabrilovich, MD, PhD – *The Wistar Institute*

Sourav Ghosh, PhD – *Yale School of Medicine*

Location: 202AB

5:10 – 5:35 p.m. **Innate Immune Checkpoints and Cancer Immunotherapy**
Sourav Ghosh, PhD – *Yale School of Medicine*

5:35 – 6 p.m. **Regulation of Myeloid-Derived Suppressor Cells in Cancer**
Dmitry I. Gabrilovich, MD, PhD – *The Wistar Institute*

6 – 6:15 p.m. **Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy**
Greg Lesinski, PhD, MPH – *Winship Cancer Institute of Emory University*

6:15 – 6:30 p.m. **Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations**
George A. Dominguez, PhD – *Anixa Biosciences*

Concurrent Session 216: Role of B cells in Immunotherapy and Toxicity

Co-Chairs:

Tullia C. Bruno, PhD – *University of Pittsburgh*

Madhav Dhodapkar, MD – *Emory University*

Location: East Salon ABC

5:10 – 5:15 p.m. **Introduction**
Madhav Dhodapkar, MD – *Emory University*

5:15 – 5:35 p.m. **Role of B cells in Tumors**
Tullia C. Bruno, PhD – *University of Pittsburgh*

- 5:35 – 5:55 p.m. **Role of B cells in Autoimmunity**
Kavita M. Dhodapkar, MD – *Emory University*
- 5:55 – 6:10 p.m. **B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB)**
Sangeetha Reddy, MD, MSci – *MD Anderson Cancer Center*
- 6:10 – 6:25 p.m. **Anti-Tumor Immune Responses in Metastatic Breast Cancer Exceptional Responder Patients**
William H. Robinson, MD, PhD – *Stanford University School of Medicine*
- 6:25 – 6:30 p.m. **Closing**
Tullia C. Bruno, PhD – *University of Pittsburgh*
- 6:35 – 7 p.m. **Award Ceremony**
Location: Hall D
- 7 – 8:30 p.m. **Poster Reception**
Location: Hall E
- 8:30 – 11:30 p.m. **The Checkpoints Band Party**
Location: Marriott Marquis Liberty Ballroom

Sunday, November 11, 2018

7 – 10 a.m. **Registration**
Location: L St. Bridge

7 – 8 a.m. **Breakfast**
Location: Hall E Foyer

7:30 – 7:35 a.m. **Annual Meeting Organizer Welcome**
Dario A.A. Vignali, PhD – *University of Pittsburgh*
Location: Hall D

Session 300: Update Session

Location: Hall D

7:35 – 8:05 a.m. **Cancer Immunotherapy Trials Network Update**
Martin A. Cheever, MD – *Fred Hutchinson Cancer Research Center*

Concurrent Session 301: Next Generation Bispecifics and Antibody-Like Molecules

Co-Chairs:

Ignacio Melero, MD, PhD – *FIMA - University of Navarra*

Farhad Ravandi, MD – *University of Texas MD Anderson Cancer Center*

Location: Hall D

8:05 – 8:10 **Introduction**
Ignacio Melero, MD, PhD – *FIMA-University of Navarra*

8:10 – 8:35 a.m. **Next Generation T Cell Bispecific Antibodies and Fusion Proteins for Cancer Immunotherapy**
Pablo Umaña, PhD – *Roche Glycart AG*

8:35 – 9:00 a.m. **Blinatumomab: Can We Improve Efficacy Using Checkpoint Inhibitors**
Dirk Nagorsen, MD, PhD – *Amgen Inc.*

9:00 – 9:25 a.m. **Chimeric Antibodies in AML: Hope or Reality?**
Farhad Ravandi, MD – *University of Texas MD Anderson Cancer Center*

9:25 – 9:40 a.m. **A new immunomodulatory strategy of inhibiting the glyco-immune checkpoint axis with EAGLE technology to treat cancer**
Li Peng, PhD – *Palleon Pharmaceuticals*

9:40 – 9:55 a.m. **FS120 mAb2, a dual agonist bispecific antibody targeting OX40 and CD137, activates T cells in**

in vitro and induces potent, FcγR-independent anti-tumour activity

Miguel Gaspar, PhD – *F-star Biotechnology Ltd*

9:55 – 10:10 a.m. **Immuno-oncology tHERApY with HERA-GITRL: the novel hexavalent human GITR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality**

David M. Richards – *Apogenix AG*

10:10 – 10:15 a.m. **Closing**

Farhad Ravandi, MD – *University of Texas MD Anderson Cancer Center*

10:15 – 10:30 a.m. **Break**

Concurrent Session 302: Clinical Trials Session

Co-Chairs:

Michael Atkins, MD – *Georgetown-Lombardi Comprehensive Cancer Center*

Mario Sznol, MD – *Yale Cancer Center*

Location: 202AB

8:10 – 8:25 a.m. **Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors**

Amod Sarnaik, MD – *H. Lee Moffitt Cancer Center & Research*

8:25 – 8:40 a.m. **Infusion of TGFβ-resistant EBV-specific T-cells post cytoreductive chemotherapy is safe and associated with clinical benefit in patients with recurrent/metastatic NPC**

Christopher DeRenzo, MD – *St. Jude Children's Research Hospital*

8:40 – 8:55 a.m. **Expert Discussant**

Cara Haymaker, PhD – *University of Texas MD Anderson Cancer Center*

8:55 – 9:05 a.m. **Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancer**

Carsten Krieg, PhD – *Medical University of South Carolina*

9:05 – 9:20 a.m. **Monalizumab in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): clinical and translational biomarker results**

Roger Cohen – *University of Pennsylvania*

9:20 – 9:35 a.m. **Combination of subcutaneous selicrelumab (CD40 agonist) and vanucizumab (anti-Ang2/VEGF) in patients with solid tumors demonstrates early clinical activity and a favorable safety profile**

Emiliano Calvo, MD, PhD – *START Madrid*

9:35 – 9:50 a.m. **A phase 1, open-label, dose-escalation study of enoblituzumab in combination with pembrolizumab in patients with select solid tumors**
Charu Aggarwal, MD, MPH – *University of Pennsylvania*

9:50 – 10:05 a.m. **Phase 2 trial of mocetinostat in combination with durvalumab in NSCLC patients with progression on prior checkpoint inhibitor therapy**
Manish Patel, DO – *University of Minnesota Medical Center*

10:05 – 10:15 a.m. **Expert Discussant**
Elad Sharon, MD, MPH – *National Institutes of Health*

Concurrent Session 303: Update Session

Location: Hall D

10:30 – 10:45 a.m. **Immunoscore Update**
Jerome Galon, PhD – *Universite Pierre Et Marie Curie, Sorbonne Universites*

Concurrent Session 304: Hot Topic Symposium

Location: Hall D

Lessons from Recent Immuno-Oncology Trials - When Activity Estimation Diverges from Therapeutic Confirmation

Co-Chairs:

Helen Chen, MD – *National Cancer Institute*

Marc Theoret, MD – *U.S. Food & Drug Administration, OHOP*

10:45 – 10:50 a.m. **Introduction**
Marc Theoret, MD – *U.S. Food & Drug Administration, OHOP*

10:50 – 11:05 a.m. **Considering Recent Clinical Failures to Inform Novel Immuno-Therapeutics Development**
Jason J. Luke, MD, FACP – *University of Chicago*

11:05 – 11:20 a.m. **Dosing and Dosage Regimen**
Renzo Canetta, MD

11:20 – 11:35 a.m. **Biomarker Selection Considerations**
Roy S. Herbst, MD, PhD – *Yale Cancer Center*

11:35 – 11:50 a.m. **Clinical Development Strategy/Trial Design**
Mario Sznol, MD – *Yale Cancer Center*

11:50 a.m. – 12:15 p.m.

Panel Discussion

Moderators: Helen Chen, MD – *National Cancer Institute*
Marc Theoret, MD – *U.S. Food & Drug Administration, OHOP*

Panelists: Renzo Canetta, MD

Roy S. Herbst, MD, PhD – *Yale Cancer Center*

Jason J. Luke, MD, FACP – *University of Chicago*

Rajeshwari Sridhara, PhD – *U.S. Food & Drug Administration*

Mario Sznol, MD – *Yale Cancer Center*

12:15 – 12:20 p.m.

Thank you for attending SITC 2018!